Federated Hermes’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Federated Hermes’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3	Closed	-$28	–	2242
2023 Q3	$28	Buy	+3	New	+$60	﹤0.01%	2082
2020 Q2	–	Sell	-6	Closed	-$1K	–	2403
2020 Q1	$1K	Buy	+6	New	+$1.91K	﹤0.01%	2171
2014 Q4	–	Sell	-1	Closed	-$4K	–	2065
2014 Q3	$4K	Buy	+1	New	+$5.28K	﹤0.01%	1882

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes's EIGR Position: Q4 2023 in Review

Federated Hermes sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 3 shares — an estimated $28 sold.

Federated Hermes first reported a position in EIGR in Q3 2014 and held it in 3 quarters. The position peaked at $4K in Q3 2014. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

Federated Hermes reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Federated Hermes sold 3 Eiger BioPharmaceuticals, Inc. shares in Q4 2023, an estimated $28.
Federated Hermes first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 3 quarters.
Federated Hermes's Eiger BioPharmaceuticals, Inc. position peaked at $4K in Q3 2014.
43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on Federated Hermes's 13F filing for Q4 2023, filed 31 Jan 2024.